Background Follicle-stimulating hormone (FSH) is used empirically to treat normogonadotropic primary spermatogenic failure, but response is highly variable and reliable predictors of efficacy are lacking. Recent authors have suggested incorporating transrectal ultrasonography (TRUS) into the diagnostic work-up to identify and treat male accessory gland conditions before starting gonadotropin therapy; however, the clinical impact of this TRUS-based selection strategy on the response to FSH therapy has not been directly quantified. Aim This study aimed to perform deep phenotyping of men with normogonadotropic primary spermatogenic failure undergoing FSH therapy and to determine whether a TRUS-based diagnostic and therapeutic selection pathway was associated with a greater seminal response to exogenous FSH compared with a conventional, non-TRUS-guided approach. Materials and methods In this single-centre prospective observational study, 113 men with normogonadotropic (FSH 1.5-8.0 IU/L) primary spermatogenic failure, defined according to the pathophysiology-based classification of male factor infertility as category IIIB, were treated with exogenous FSH (urofollitropin, follitropin alfa, or follitropin beta) at the Unit of Andrology and Reproductive Medicine, Padua University Hospital. The selected group (S, n=79) was prospectively enrolled and underwent a diagnostic pathway incorporating TRUS to exclude or, when appropriate, treat clinically relevant sub-obstructive or inflammatory conditions before FSH therapy. The non-selected group (NS, n=34) was retrospectively identified from clinical records and served as the comparison group; these patients had not undergone the TRUS-based selection. Primary endpoints were a post-treatment doubling of sperm concentration and total sperm count relative to baseline. Associations were quantified through logistic regression (odds ratios, ORs, with 95% confidence intervals), adjusting for age, baseline semen parameters, FSH, bilateral testicular volume (BTV), LH, and total testosterone (TT). Secondary analyses addressed conventional semen-quality parameters, FSH formulation, FSHB/FSHR gene polymorphisms, and derived endocrine-testicular indices, evaluated using Receiver Operating Characteristic (ROC) curves (area under the curve, AUC). Results S status was strongly associated with both primary endpoints, with response rates 52.8 and 54.5 percentage points higher than in NS patients for sperm concentration and total sperm count doubling, respectively (unadjusted ORs 10.65 and 12.09, both p<0.001). The association remained strong after multivariable adjustment (adjusted ORs 10.4-14.1 across models, all p<0.001). No conventional demographic, endocrine, or testicular variable, evaluated individually, approached this magnitude of association. Progressive and total motility and vitality improved significantly within the S subgroup but not in NS patients, although direct between-group comparisons of change did not reach statistical significance. No significant difference in response was observed across the three FSH formulations. Exploratory genetic and derived-index analyses did not identify additional robust predictors of treatment response, whereas the S/NS classification showed greater discrimination for both primary outcomes. Conclusion In this cohort of men with normogonadotropic primary spermatogenic failure, TRUS-based diagnostic selection was the strongest and most consistent predictor of seminal response to FSH therapy, outperforming conventional clinical, endocrine, and genetic markers, as well as more complex composite indices. These findings support the incorporation of a structured TRUS-based pathway into the pre-treatment work-up of candidates for FSH therapy, while prospective, multicentre studies with pregnancy and live-birth endpoints are needed to confirm these findings.

Background Follicle-stimulating hormone (FSH) is used empirically to treat normogonadotropic primary spermatogenic failure, but response is highly variable and reliable predictors of efficacy are lacking. Recent authors have suggested incorporating transrectal ultrasonography (TRUS) into the diagnostic work-up to identify and treat male accessory gland conditions before starting gonadotropin therapy; however, the clinical impact of this TRUS-based selection strategy on the response to FSH therapy has not been directly quantified. Aim This study aimed to perform deep phenotyping of men with normogonadotropic primary spermatogenic failure undergoing FSH therapy and to determine whether a TRUS-based diagnostic and therapeutic selection pathway was associated with a greater seminal response to exogenous FSH compared with a conventional, non-TRUS-guided approach. Materials and methods In this single-centre prospective observational study, 113 men with normogonadotropic (FSH 1.5-8.0 IU/L) primary spermatogenic failure, defined according to the pathophysiology-based classification of male factor infertility as category IIIB, were treated with exogenous FSH (urofollitropin, follitropin alfa, or follitropin beta) at the Unit of Andrology and Reproductive Medicine, Padua University Hospital. The selected group (S, n=79) was prospectively enrolled and underwent a diagnostic pathway incorporating TRUS to exclude or, when appropriate, treat clinically relevant sub-obstructive or inflammatory conditions before FSH therapy. The non-selected group (NS, n=34) was retrospectively identified from clinical records and served as the comparison group; these patients had not undergone the TRUS-based selection. Primary endpoints were a post-treatment doubling of sperm concentration and total sperm count relative to baseline. Associations were quantified through logistic regression (odds ratios, ORs, with 95% confidence intervals), adjusting for age, baseline semen parameters, FSH, bilateral testicular volume (BTV), LH, and total testosterone (TT). Secondary analyses addressed conventional semen-quality parameters, FSH formulation, FSHB/FSHR gene polymorphisms, and derived endocrine-testicular indices, evaluated using Receiver Operating Characteristic (ROC) curves (area under the curve, AUC). Results S status was strongly associated with both primary endpoints, with response rates 52.8 and 54.5 percentage points higher than in NS patients for sperm concentration and total sperm count doubling, respectively (unadjusted ORs 10.65 and 12.09, both p<0.001). The association remained strong after multivariable adjustment (adjusted ORs 10.4-14.1 across models, all p<0.001). No conventional demographic, endocrine, or testicular variable, evaluated individually, approached this magnitude of association. Progressive and total motility and vitality improved significantly within the S subgroup but not in NS patients, although direct between-group comparisons of change did not reach statistical significance. No significant difference in response was observed across the three FSH formulations. Exploratory genetic and derived-index analyses did not identify additional robust predictors of treatment response, whereas the S/NS classification showed greater discrimination for both primary outcomes. Conclusion In this cohort of men with normogonadotropic primary spermatogenic failure, TRUS-based diagnostic selection was the strongest and most consistent predictor of seminal response to FSH therapy, outperforming conventional clinical, endocrine, and genetic markers, as well as more complex composite indices. These findings support the incorporation of a structured TRUS-based pathway into the pre-treatment work-up of candidates for FSH therapy, while prospective, multicentre studies with pregnancy and live-birth endpoints are needed to confirm these findings.

DEEP PHENOTYPING OF MALE FACTOR INFERTILITY IMPROVES RESPONSE TO FSH TREATMENT IN NORMOGONADOTROPIC OLIGO-ASTHENOZOOSPERMIA

POMI, ANNALISA
2025/2026

Abstract

Background Follicle-stimulating hormone (FSH) is used empirically to treat normogonadotropic primary spermatogenic failure, but response is highly variable and reliable predictors of efficacy are lacking. Recent authors have suggested incorporating transrectal ultrasonography (TRUS) into the diagnostic work-up to identify and treat male accessory gland conditions before starting gonadotropin therapy; however, the clinical impact of this TRUS-based selection strategy on the response to FSH therapy has not been directly quantified. Aim This study aimed to perform deep phenotyping of men with normogonadotropic primary spermatogenic failure undergoing FSH therapy and to determine whether a TRUS-based diagnostic and therapeutic selection pathway was associated with a greater seminal response to exogenous FSH compared with a conventional, non-TRUS-guided approach. Materials and methods In this single-centre prospective observational study, 113 men with normogonadotropic (FSH 1.5-8.0 IU/L) primary spermatogenic failure, defined according to the pathophysiology-based classification of male factor infertility as category IIIB, were treated with exogenous FSH (urofollitropin, follitropin alfa, or follitropin beta) at the Unit of Andrology and Reproductive Medicine, Padua University Hospital. The selected group (S, n=79) was prospectively enrolled and underwent a diagnostic pathway incorporating TRUS to exclude or, when appropriate, treat clinically relevant sub-obstructive or inflammatory conditions before FSH therapy. The non-selected group (NS, n=34) was retrospectively identified from clinical records and served as the comparison group; these patients had not undergone the TRUS-based selection. Primary endpoints were a post-treatment doubling of sperm concentration and total sperm count relative to baseline. Associations were quantified through logistic regression (odds ratios, ORs, with 95% confidence intervals), adjusting for age, baseline semen parameters, FSH, bilateral testicular volume (BTV), LH, and total testosterone (TT). Secondary analyses addressed conventional semen-quality parameters, FSH formulation, FSHB/FSHR gene polymorphisms, and derived endocrine-testicular indices, evaluated using Receiver Operating Characteristic (ROC) curves (area under the curve, AUC). Results S status was strongly associated with both primary endpoints, with response rates 52.8 and 54.5 percentage points higher than in NS patients for sperm concentration and total sperm count doubling, respectively (unadjusted ORs 10.65 and 12.09, both p<0.001). The association remained strong after multivariable adjustment (adjusted ORs 10.4-14.1 across models, all p<0.001). No conventional demographic, endocrine, or testicular variable, evaluated individually, approached this magnitude of association. Progressive and total motility and vitality improved significantly within the S subgroup but not in NS patients, although direct between-group comparisons of change did not reach statistical significance. No significant difference in response was observed across the three FSH formulations. Exploratory genetic and derived-index analyses did not identify additional robust predictors of treatment response, whereas the S/NS classification showed greater discrimination for both primary outcomes. Conclusion In this cohort of men with normogonadotropic primary spermatogenic failure, TRUS-based diagnostic selection was the strongest and most consistent predictor of seminal response to FSH therapy, outperforming conventional clinical, endocrine, and genetic markers, as well as more complex composite indices. These findings support the incorporation of a structured TRUS-based pathway into the pre-treatment work-up of candidates for FSH therapy, while prospective, multicentre studies with pregnancy and live-birth endpoints are needed to confirm these findings.
2025
DEEP PHENOTYPING OF MALE FACTOR INFERTILITY IMPROVES RESPONSE TO FSH TREATMENT IN NORMOGONADOTROPIC OLIGO-ASTHENOZOOSPERMIA
Background Follicle-stimulating hormone (FSH) is used empirically to treat normogonadotropic primary spermatogenic failure, but response is highly variable and reliable predictors of efficacy are lacking. Recent authors have suggested incorporating transrectal ultrasonography (TRUS) into the diagnostic work-up to identify and treat male accessory gland conditions before starting gonadotropin therapy; however, the clinical impact of this TRUS-based selection strategy on the response to FSH therapy has not been directly quantified. Aim This study aimed to perform deep phenotyping of men with normogonadotropic primary spermatogenic failure undergoing FSH therapy and to determine whether a TRUS-based diagnostic and therapeutic selection pathway was associated with a greater seminal response to exogenous FSH compared with a conventional, non-TRUS-guided approach. Materials and methods In this single-centre prospective observational study, 113 men with normogonadotropic (FSH 1.5-8.0 IU/L) primary spermatogenic failure, defined according to the pathophysiology-based classification of male factor infertility as category IIIB, were treated with exogenous FSH (urofollitropin, follitropin alfa, or follitropin beta) at the Unit of Andrology and Reproductive Medicine, Padua University Hospital. The selected group (S, n=79) was prospectively enrolled and underwent a diagnostic pathway incorporating TRUS to exclude or, when appropriate, treat clinically relevant sub-obstructive or inflammatory conditions before FSH therapy. The non-selected group (NS, n=34) was retrospectively identified from clinical records and served as the comparison group; these patients had not undergone the TRUS-based selection. Primary endpoints were a post-treatment doubling of sperm concentration and total sperm count relative to baseline. Associations were quantified through logistic regression (odds ratios, ORs, with 95% confidence intervals), adjusting for age, baseline semen parameters, FSH, bilateral testicular volume (BTV), LH, and total testosterone (TT). Secondary analyses addressed conventional semen-quality parameters, FSH formulation, FSHB/FSHR gene polymorphisms, and derived endocrine-testicular indices, evaluated using Receiver Operating Characteristic (ROC) curves (area under the curve, AUC). Results S status was strongly associated with both primary endpoints, with response rates 52.8 and 54.5 percentage points higher than in NS patients for sperm concentration and total sperm count doubling, respectively (unadjusted ORs 10.65 and 12.09, both p<0.001). The association remained strong after multivariable adjustment (adjusted ORs 10.4-14.1 across models, all p<0.001). No conventional demographic, endocrine, or testicular variable, evaluated individually, approached this magnitude of association. Progressive and total motility and vitality improved significantly within the S subgroup but not in NS patients, although direct between-group comparisons of change did not reach statistical significance. No significant difference in response was observed across the three FSH formulations. Exploratory genetic and derived-index analyses did not identify additional robust predictors of treatment response, whereas the S/NS classification showed greater discrimination for both primary outcomes. Conclusion In this cohort of men with normogonadotropic primary spermatogenic failure, TRUS-based diagnostic selection was the strongest and most consistent predictor of seminal response to FSH therapy, outperforming conventional clinical, endocrine, and genetic markers, as well as more complex composite indices. These findings support the incorporation of a structured TRUS-based pathway into the pre-treatment work-up of candidates for FSH therapy, while prospective, multicentre studies with pregnancy and live-birth endpoints are needed to confirm these findings.
Male infertility
FSH therapy
Personalized therapy
File in questo prodotto:
File Dimensione Formato  
DEEP PHENOTYPING OF MALE INFERTILITY IMPROVES RESPONSE TO FSH TREATMENT IN NORMOGONADOTROPIC OLIGO-ASTHENOZOOSPERMIA.pdf

Accesso riservato

Dimensione 2.35 MB
Formato Adobe PDF
2.35 MB Adobe PDF

The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12608/119122